Other OTC - Delayed Quote • USD
Bayer Aktiengesellschaft (BAYRY)
At close: April 26 at 3:59 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | -- |
| Avg. Estimate | 0.42 | 0.34 | 1.38 | 0 |
| Low Estimate | 0.42 | 0.34 | 1.38 | 0 |
| High Estimate | 0.42 | 0.34 | 1.38 | 0 |
| Year Ago EPS | 0.79 | 0.33 | 1.73 | 1.38 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | 15.91B | 12.08B | 50.82B | 52.36B |
| Low Estimate | 15.91B | 12.08B | 50.82B | 52.36B |
| High Estimate | 15.91B | 12.08B | 50.82B | 52.36B |
| Year Ago Sales | 15.44B | 12.02B | 51.5B | 50.82B |
| Sales Growth (year/est) | 3.00% | 0.50% | -1.30% | 3.00% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.54 | 0.31 | 0.27 | 0.45 |
| EPS Actual | 0.79 | 0.33 | 0.1 | 0.5 |
| Difference | 0.25 | 0.02 | -0.17 | 0.05 |
| Surprise % | 46.30% | 6.50% | -63.00% | 11.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.42 | 0.34 | 1.38 | 0 |
| 7 Days Ago | 0.42 | 0.34 | 1.38 | 8.23 |
| 30 Days Ago | 0.42 | 0.34 | 1.38 | 8.23 |
| 60 Days Ago | 0 | 0 | 1.57 | 8.23 |
| 90 Days Ago | 0 | 0 | 1.57 | 8.23 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | 1 |
Growth Estimates
| CURRENCY IN USD | BAYRY | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -46.80% | -- | -- | 6.50% |
| Next Qtr. | 3.00% | -- | -- | 12.00% |
| Current Year | -20.20% | -- | -- | 5.30% |
| Next Year | -- | -- | -- | 13.10% |
| Next 5 Years (per annum) | 4.70% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -4.95% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Downgrade | Citigroup: Buy to Neutral | 10/1/2020 |
| Downgrade | Jefferies: Buy to Hold | 8/15/2018 |
| Upgrade | Citigroup: Neutral to Buy | 8/25/2016 |
| Upgrade | Morgan Stanley: Equal-Weight to Overweight | 12/2/2014 |
Related Tickers
RHHBY Roche Holding AG
30.25
+0.77%
SNY Sanofi
49.13
-0.47%
GSK GSK plc
41.11
+0.49%
NVS Novartis AG
97.44
-1.64%
ALPMY Astellas Pharma Inc.
9.55
+0.10%
AMGN Amgen Inc.
269.98
+0.22%
AZN AstraZeneca PLC
75.17
+0.19%
BMY Bristol-Myers Squibb Company
44.85
+0.34%
ROG.SW Roche Holding AG
221.00
+1.01%
GILD Gilead Sciences, Inc.
65.42
+0.23%